All In Biotech

Drug Trial Radar · NCT06539507

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

76

Actual

Start

Sep 26, 2024

Primary completion

Dec 2026

Study completion Feb 2027

Sponsor

Lead sponsor
BioCryst PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.

Conditions

  • Netherton Syndrome

Interventions

  • BCX17725Drug

    BCX17725 for injection

  • PlaceboDrug

    Placebo for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs)Time frame: From screening through EOS (ie, through Day 78 in Parts 1 and 3, and Day 106 in Part 2)
  2. Change from baseline in Ichthyosis Area and Severity Index (IASI) score at Week 12 (Part 4)Time frame: From baseline to Week 12

Locations

12 sites in 5 countries. Site status is shown where the registry gives one.

  • Stanford University School of Medicine

    Palo Alto, California

  • Therapeutics Clinical Research

    San Diego, California

  • Yale Center for Clinical Investigation

    New Haven, Connecticut

  • Northwestern Dermatology CTU

    Chicago, Illinois

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • Westmead Hospital - Department of Dermatology

    Sydney, New South Wales, Australia

  • Nucleus Network

    Brisbane, Queensland, Australia

  • Veracity Clinical Research

    Brisbane, Queensland, Australia

  • Hôpital Saint-Louis

    Paris, France

  • Universitätsklinikum Heidelberg

    Heidelberg, Germany

  • Maastricht Universitair Medisch Centrum (MUMC+)

    Maastricht, Netherlands

  • Erasmus Universitair Medisch Centrum (EMC)

    Rotterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.